Psychopharmacology in Cancer

42Citations
Citations of this article
94Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Depression, anxiety, delirium, and other psychiatric symptoms are highly prevalent in the cancer setting, and pharmacological intervention is an important component in the overall psychosocial care of the patient. Psychopharmacology is also used as a primary or adjuvant treatment for the management of cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropathic pain, nausea, fatigue, and hot flashes. Psychiatrists, oncologists, and palliative care physicians working as members of a multidisciplinary team have the opportunity to target multiple symptoms that negatively affect a patient’s quality of life with the strategic use of psychotropic medications when deemed appropriate. This article aims to review the indications for use of antidepressants, psychostimulants, anxiolytics, antipsychotics, and mood stabilizers in oncology. An updated review of the relevant literature is discussed and referenced in each section.

Cite

CITATION STYLE

APA

Thekdi, S. M., Trinidad, A., & Roth, A. (2015, January 1). Psychopharmacology in Cancer. Current Psychiatry Reports. Current Medicine Group LLC 1. https://doi.org/10.1007/s11920-014-0529-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free